MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New drug substantially extends survival in pancreatic cancer

Back to pancreas Blogs list Cancer blog  


Subscribe To Pancreas RSS Feed  RSS content feed What is RSS feed?

New drug substantially extends survival in pancreatic cancer




A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreas cancer, scientists report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

European researchers led by Prof. Matthias Lhr from the Karolinska Institute reviewed the efficacy and safety of three different doses of cationic lipid complexed paclitaxel (EndoTAG-1) administered twice weekly, in combination with weekly infusions of gemcitabine, in comparison to gemcitabine alone, in 200 patients with pancreatic adenocarcinoma.



New drug substantially extends survival in pancreatic cancer

"EndoTAG consists of charged particles that bind preferentially to the fast-growing endothelial cells in new blood vessels being formed by tumors," Prof. Lhr explained. "The drug, paclitaxel, is then released and thus directly reaches an important target in tumors, i.e. the vessels. Paclitaxel itself is not very efficient in pancreratic cancer".

After following patients for a year, the scientists observed that therapy with such combination led to a substantially extended median survival time in comparison to standard treatment. Patients given gemcitabine alone survived on average 7.2 months, in comparison to up to 13.6 months for patients who received repeated doses of the combination (EndoTAG plus gemcitabine).

"These results are the best I have ever seen in palliative therapy in pancreas cancer," Prof. Lhr said. "The results are really excellent and a phase III study is in the making".


Posted by: Sue    Source




Did you know?
A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreas cancer, scientists report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

Medicineworld.org: New drug substantially extends survival in pancreatic cancer

Advances in pancreatic cancer treatment| Detailed information on pancreatic cancer| Pancreas cancer main| Major topics in pancreatic cancer| Overview of pancreatic cancer| Pancreatic cancer resources| More resources for pancreatic cancer| Resources 3 for pancreatic cancer| Resources4 for pancreatic cancer| Resources5 for pancreatic cancer| Resources6 for pancreatic cancer| Resources7 for pancreatic cancer| Resources8 for pancreatic cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.